We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I Trial of Oral PX-866

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00726583
Recruitment Status : Completed
First Posted : August 1, 2008
Last Update Posted : May 17, 2018
Information provided by (Responsible Party):
Seagen Inc. ( Cascadian Therapeutics Inc. )

Brief Summary:
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: PX-866 Phase 1

Detailed Description:
PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients With Advanced Solid Tumors
Study Start Date : June 2008
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Arm Intervention/treatment
Experimental: Investigational Drug
Dose Escalation
Drug: PX-866
Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity

Primary Outcome Measures :
  1. Determine the MTD of PX-866 [ Time Frame: 28 days ]
  2. Evaluate the safety profile of PX-866 [ Time Frame: 28 days ]
  3. Evaluate pharmacodynamic measures of the effects of PX-866 on the phosphatidylinositol-3 kinase (PI-3K) pathway and related tumor markers. [ Time Frame: 28 days ]
  4. Determine the PK profile of PX-866. [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Evaluate the anti-tumor activity of PX-866 in patients with advanced malignancies. [ Time Frame: 56 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of advanced solid tumor and has failed or is intolerant of standard therapy, or for whom standard therapy does not exist.
  • 18 years of age or older.
  • ECOG performance status 0 to 1.
  • Predicted life expectancy of at least 12 weeks.
  • Discontinued prior chemotherapy or other investigational agents for at least three weeks prior to receiving the first dose of study drug (six weeks for mitomycin C, nitrosureas,vaccines,or antibody therapy)and recovered from the toxic effects of the prior treatment (recovered to baseline or ≤grade 1 per Common Toxicity Criteria for Adverse Events (CTCAE)).
  • Discontinued any radiation therapy for at least four weeks and have recovered from all radiation-related toxicities (recovered to baseline or ≤CTCAE grade 1) prior to receiving the first dose of study drug. Palliative radiation of 10 fractions or less is permitted and a four week interval is not necessary (also allowed during therapy).
  • Adequate hematologic function as defined by the following: WBC count >3,000 cells/μL; platelets >100,000/μL; hemoglobin >9 g/dL (may be transfused to this level); ANC >1500 cells/μL.
  • Adequate hepatic function as defined by the following: bilirubin <1.5 mg/dL; aspartate aminotransaminase (AST/SGOT) & alanine aminotransferase (ALT/SGPT) <2.5 x ULN or <5 x ULN if due to metastatic disease.
  • Adequate renal function as defined by serum creatinine level <1.5 mg/dL.

Exclusion Criteria:

  • Any active infection at study entry.
  • Known diabetes or fasting blood glucose>160 mg/dL.
  • Known human immunodeficiency virus (HIV).
  • Any serious concomitant systemic disorders that in the opinion of the investigator would place the patient at excessive or unacceptable risk of toxicity.
  • Surgery within the four weeks prior to the first dose
  • Significant central nervous system (CNS) or psychiatric disorder(s) that preclude the ability of the patient to provide informed consent.
  • Known or suspected brain metastases that have not received adequate therapy or for which the patient requires treatment with steroids or anticonvulsants. In the case of previously treated brain metastases, a minimum four week interval between completion of radiation therapy and registration on study with radiologic evidence of stable or responding brain metastases is required. In the setting of previous CNS metastasectomy, adequate (minimum four week) recovery from surgery and/or radiation therapy should be documented.
  • Leptomeningeal brain metastases should be excluded regardless of whether the metastases have been treated or not.
  • History of seizures, non-healing wounds, or arterial thrombosis.
  • Unstable atrial or ventricular arrhythmias requiring control by medication; any cardiac ischemic event experienced within the preceding six months; prior history of congestive heart failure requiring therapy.
  • Breastfeeding or pregnant (confirmed by serum β-HCG within 10 days prior to the start of study treatment if applicable).
  • Total gastrectomy, partial bowel obstruction or any gastrointestinal condition that may interfere with absorption of the study medication.
  • Any condition that could jeopardize the safety of the patient and compliance with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00726583

Layout table for location information
United States, Colorado
University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80045
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Cascadian Therapeutics Inc.
Layout table for additonal information
Responsible Party: Cascadian Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00726583    
Other Study ID Numbers: PX-866-001
First Posted: August 1, 2008    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: October 2011
Keywords provided by Seagen Inc. ( Cascadian Therapeutics Inc. ):
Solid Tumors
PI3 kinase